Genelux Corp Share Price

NASDAQ: GNLX

Small Cap

$3.90

-0.19

(-4.65%)

as on September 18, 2025 at 1:29 am IST

$₹

Genelux Corp Stock Performance

as on September 18, 2025 at 1:29 am IST

Day's High
$3.9
Day's Price Range
$4.21
$3.9
7.95%
Upside
52 Week's Low
52 Week's High
$1.95
52-Week Price Range
$5.89
$3.9
50.00%
Downside
50.90%
Upside

Genelux Corp share price movements today

Previous Close: $4.09
Open: $4.03
Volume: 409.0K
Day's Low - High: $3.9 - $4.21
52 Week Low - High: $1.95 - $5.89

Genelux Corp Historical Returns

1 Month Return: + 10.45 %
3 Month Return: + 33.9 %
1 Year Return: + 59.59 %
3 Year Return: 0 %
5 Year Return: 0 %

Genelux Corp Stock Fundamentals & Key Indicators

Check Genelux Corp market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$154.5M

EPS (TTM)

-0.868

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-2.58

Industry PE ratio

0

P/B Ratio

0

PEG Ratio

0

EBITDA

-32.1M

Revenue (TTM)

-

Profit Margin

0.00%

Return On Equity TTM

15568000.00%

Genelux Corp Stock Valuation

Track how Genelux Corp P/E has moved over time to understand its valuation trends.

Genelux Corp in the last 5 years

Overview
Trends

Lowest (0.00x)

September 18, 2025

Industry (0.00x)

September 18, 2025

Today (-2.58x)

September 18, 2025

Highest (0.00x)

September 18, 2025

LowHigh

Today’s Price to Earnings Ratio: -2.58x

Genelux Corp vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Genelux Corp with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %
Genelux Corp	BUY	$154.5M	NA	-2.58	0.00%
Alnylam Pharmaceuticals, Inc.	BUY	$60.5B	248.74%	-505.15	-12.96%
Beone Medicines Ltd	NA	$38.7B	NA	NA	-3.89%
Vertex Pharmaceuticals Incorporated	BUY	$99.3B	45.88%	27.56	31.86%
Regeneron Pharmaceuticals, Inc.	BUY	$60.9B	5.45%	14.49	31.37%

Stock Returns calculator for Genelux Corp Stock including INR - Dollar returns

The Genelux Corp stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

1Y

Genelux Corp investment value today

Current value as on today

₹1,64,137

Returns

₹64,137

(+64.14%)

Returns from Genelux Corp Stock

₹59,184 (+59.18%)

Dollar Returns*

₹4,953 (+4.95%)

Analyst Recommendation on Genelux Corp Stock

Based on 10 analysts

BUY

90.00%

Buy

10.00%

Hold

0.00%

Sell

Based on 10 analysts, 90% of analysts recommend a 'BUY' rating for Genelux Corp. Average target price of $18

Genelux Corp Share Price Target

Get share price movements and forecasts by analysts on Genelux Corp.

What analysts predicted

78.33%UPSIDE

Target Price

$18

Current Price

$3.9

Analyzed by

10 Analysts

Target

$18.00

Genelux Corp target price $18, a slight upside of 78.33% compared to current price of $3.9. According to 10 analysts rating.

Genelux Corp Stock's Interest Amongst Investors

Search interest for Genelux Corp Stock has decreased by -38% in the last 30 days, reflecting a downward trend in search activity.

Time period: August 19, 2025 to September 18, 2025

Change:-38% versus previous 30 day period

Genelux Corp Quarterly Profit & Loss

All numbers in Millions USD

	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025
Total Revenue	0	-	-	1	0	-	-	0	0	-
Gross Profit	0	0	0	0	0	0	0	0	0	0
Operating Income	-6	-5	-5	-7	-8	-6	-6	-9	-7	-7
EBITDA	-9	-5	-5	-6	-7	-6	-6	-8	-7	-7
Interest Expense	0	0	0	0	-	-	-	-	-	-
Depreciation	0	0	0	0	0	0	0	0	0	0
Income Before Tax	-10	-5	-5	-6	-7	-6	-6	-8	-7	-7
Income Tax Expense	4	0	0	-4	0	-	-	-	-	-
Net Income	-10	-5	-5	-6	-7	-6	-6	-8	-7	-7
Net Profit Margin	-6096.47%	0.00%	0.00%	-462.23%	-98125.00%	0.00%	0.00%	-1001.79%	-1657.52%	0.00%

Genelux Corp Annual Profit & Loss

All numbers in Millions USD

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Revenue	-	-	11	0	0
Gross Profit	0	0	10	0	0
Operating Income	-12	-14	-3	-24	-31
EBITDA	-11	-13	-1	-26	-28
Interest Expense	1	1	1	3	-
Depreciation	0	0	0	1	0
Income Before Tax	-13	-16	-4	-28	-29
Income Tax Expense	1	1	1	0	-
Net Income	-14	-17	-5	-28	-29
Net Profit Margin	0.00%	0.00%	-47.05%	-16645.29%	-373362.50%

Genelux Corp Quarterly Cash Flow

All numbers in Millions USD

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025
Net Income	-5	-5	-6	-7	-6	-6	-8	-7	-7
Operating Cash Flow	-5	-3	-6	-4	-6	-5	-4	-5	-7
Investing Cash Flow	0	0	-13	-1	-17	3	6	3	-2
Financing Cash Flow	22	6	0	0	27	-	0	9	0
Change in Cash	16	2	-20	-5	3	-1	2	7	-9

Genelux Corp Annual Cash Flow

All numbers in Millions USD

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Net Income	-13	-16	-5	-28	-29
Operating Cash Flow	-7	-6	-3	-20	-21
Investing Cash Flow	0	0	0	-14	-8
Financing Cash Flow	18	0	0	44	28
Change in Cash	10	-6	-4	9	0

Insights on Genelux Corp

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

POSITIVE IMPACT
Price Rise
In the last 7 days, GNLX stock has moved up by 7.1%
POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 3 quarters, -8.97M → -7.45M (in $), with an average increase of 10.2% per quarter
NO EFFECT
Against Peers
In the last 1 year, Beone Medicines Ltd has given 68.4% return, outperforming this stock by 8.8%
NEGATIVE IMPACT
Revenue Fall
Revenue is down for the last 2 quarters, 896.0K → 452.0K (in $), with an average decrease of 49.6% per quarter

About Genelux Corp

Genelux Corporation is a late clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its clinical and preclinical product candidates are intended to selectively kill tumor cells and induce a robust immune response against a patient’s tumor neoantigens. Its product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, modified strain of the vaccinia virus (VACV), a stable deoxyribonucleic acid (DNA) virus with a large engineering capacity. Olvi-Vec is developed for the treatment of multiple cancers based on the results of preclinical studies that suggest Olvi-Vec has the potential to infect and directly kill a wide range of tumor cell types in vitro and in vivo and produce an anti-tumor immune response. Its portfolio also include oncolytic vaccinia immunotherapy clinical candidates.

Organisation	Genelux Corp
Headquarters	2625 Townsgate Road, Westlake Village, CA, United States, 91361
CEO	Mr. Thomas D. Zindrick J.D.
E-voting on shares	Click here to vote

Key Management of Genelux Corp

Name	Title
Mr. Ralph Smalling B.Sc.	VP & Head of Regulatory Affairs
Mr. Thomas D. Zindrick J.D.	Chairman, CEO & President
Dr. Joseph Cappello Ph.D.	Chief Technical Officer
Mr. Matthew Pulisic M.B.A.	CFO and Principal Financial & Accounting Officer
Mr. Eric Groen J.D.	General Counsel, Corporate Secretary, Chief Compliance Officer & Head of Business Development
Dr. Yong Yu Ph.D.	Senior Vice President of Clinical Development
Prof. Paul Scigalla M.D., Ph.D.	Chief Medical Officer

FAQs

What is Genelux Corp share price today?

Genelux Corp share price today is $3.9 as on September 18, 2025 at 1:29 am IST at the close of the market. Genelux Corp share today touched a day high of $4.21 and a low of $3.9.

What is the 52 week high and 52 week low for Genelux Corp share?

Genelux Corp share touched a 52 week high of $5.89 on February 12, 2025 and a 52 week low of $1.95 on September 25, 2024. Genelux Corp stock price today i.e. September 18, 2025 at 1:29 am IST is closed at $3.9,which is 33.73% down from its 52 week high and 100.00% up from its 52 week low.

What is Genelux Corp's market capitalisation today?

Genelux Corp market capitalisation is $0.00T as on September 18, 2025 at 1:29 am IST.

How to invest in Genelux Corp Stock (GNLX) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Genelux Corp on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Genelux Corp Shares that will get you 0.3846 shares as per Genelux Corp share price of $3.9 per share as on September 18, 2025 at 1:29 am IST.

What is the minimum amount required to buy Genelux Corp Stock (GNLX) from India?

Indian investors can start investing in Genelux Corp (GNLX) shares with as little as ₹88.114 or $1 (as of September 18, 2025 at 5:36 pm IST) using the INDmoney app.
For example: If you want to invest $10 or ₹881.14 in Genelux Corp stock (as per the Rupee-Dollar exchange rate as on September 18, 2025 at 5:36 pm IST). Based on Genelux Corp share’s latest price of $3.9 as on September 18, 2025 at 1:29 am IST, you will get 2.5641 shares of Genelux Corp. Learn more about fractional shares .